Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as L606 inhalation suspension
L606 · 2 trials · 3 indications
(MSP for Cohort A): Proportion of patients with PAH or PH-ILD on a stable Tyvaso dose who would develop treatment-emergent AEs/SAEs after switching to L606 dosing for up to 2 weeks during MSP.
(OEP for Cohorts A and B): Proportion of subjects with PAH or PH-ILD, choosing to continue twice daily L606 dosing for up to 48 weeks, who would develop treatment emergent AEs/SAEs up to 48 hours after the last dose.
| Arm | Type | Description |
|---|---|---|
| L606 (in combination with nebulizer) | EXPERIMENTAL | - |
| Placebo (in combination with nebulizer) | PLACEBO_COMPARATOR | - |
| L606 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| L606 | DRUG | L606 is a liposomal version of treprostinil intended for delivery via oral inhalation using a study issued nebulizer. |
| Placebo | DRUG | Placebo will match L606 but contain no treprostinil. |
| L606 inhalation suspension | COMBINATION_PRODUCT | L606 inhalation suspension |
Inclusion Criteria: * Participant is between 18 years to 80 years old. * Has a confirmed diagnosis of ILD based on High Resolution Computed Tomography (HRCT) chest imaging. * Evidence of PH as demonstrated from Right Heart Catheterization (RHC) with the following hemodynamic parameters: * Pulmonary...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag |
| Merck & Co., Inc. | MRK | 6 | PHASE3 | Riociguat |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | Selexipag |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | TNX-103 |
| Inhibikase Therapeutics, Inc. | IKT | 1 | PHASE3 | IKT-001 |
| Gossamer Bio, Inc. | GOSS | 2 | PHASE3 | Seralutinib |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| Tectonic Therapeutic Inc | TECX | 1 | PHASE2 | TX000045- Dose A, TX000045- Dose B |
| Abbott Laboratories | ABT | 1 | N/A | Undisclosed |
L606 is an investigational small molecule being developed for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Due to Lung Disease (PH-ILD). It is administered as an inhalation suspension. The drug is currently in Phase 3 clinical development and has not been approved by the FDA.
L606 targets treprostinil, a prostacyclin analog. Treprostinil works by relaxing blood vessels in the lungs, which helps reduce pulmonary blood pressure. This mechanism is relevant for treating conditions like Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Lung Disease.
L606 is being developed by Liquidia Corporation, a biopharmaceutical company traded on the Nasdaq under the ticker symbol LQDA. The company is conducting Phase 3 clinical trials to evaluate the safety and efficacy of L606 in patients with pulmonary hypertension.
L606 is in Phase 3 clinical development. It is currently being studied in two Phase 3 trials: one evaluating safety and efficacy in PH-ILD patients and another assessing safety and tolerability in patients with PAH or PH-ILD. The drug remains investigational and is not yet approved.
L606 is being evaluated in two Phase 3 trials. NCT07285655 is a study of 344 participants with PH-ILD, recruiting across multiple countries including the US, Australia, and several European nations. NCT04691154 is a smaller study of 28 participants with PAH or PH-ILD, active in the US.
Yes, L606 is also known as L606 inhalation suspension. This refers to the drug's formulation as an inhaled suspension for treating pulmonary hypertension. The alternative name is used in clinical trial documentation to specify the route of administration.